Live
IlluminaCorvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps - Stock TitanFierceBiotechChutes & Ladders—AC Immune CEO bids adieuClinical OMICsAI in Healthcare: Symposium InsightsFierceBiotechSignant Health buys Ametris to unite data streams in clinical trialsScienceDid this scientist go too far trying to save Ecuador’s wildlife?Endpoints NewsEncoded's gene therapy reduced seizures in Dravet syndromeClinical OMICsA Retina’s Biological Age Can Predict Osteoporosis RiskClinical OMICsWireless Stress Detector Offers Multiple Medical UsesEndpoints NewsASGCT dispatch: In vivo CAR-T is everywhere, but still preclinicalClinical OMICsPrior Heart Attack Linked to Faster Cognitive Decline Over TimeBioPharma DiveCreate Medicines raises $122M to bolster in vivo CAR-T therapiesFierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS
FierceBiotech Mar 30, 2026

Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies

Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies

Original
Body unavailable. Use the original source.